Health Technology Assessment

CIRS RD Briefing 89 – Review of HTA outcomes and timelines in Australia, Canada, Europe and the UK 2018-2022

This R&D Briefing presents data from HTADock, an ongoing metrics study that collects publicly available data on new active substances (NASs) appraised by key international HTA agencies, each with [...]

2023-09-28T15:51:28+00:00September 28th, 2023|Tags: , , |

Regulatory, HTA and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement

Background: Multi-stakeholder interactions have evolved at product and policy levels. There is a need to assess the current and future landscape of interactions between companies, and regulatory and HTA agencies [...]

2023-10-31T16:46:26+00:00April 30th, 2023|Tags: , |

Evolution of HTA practice and approaches from the perspectives of HTA agencies and pharmaceutical industry

Health technology assessment (HTA) has emerged as an important tool to support healthcare decision-makers to make rational reimbursement decisions, with the ultimate purpose of promoting an efficient healthcare system. [...]

CIRS RD Briefing 86 – Review of HTA outcomes and timelines in Australia, Canada and Europe 2017-2021

The Briefing presents data from HTADock, an ongoing metrics study that collects data on new active substances (NASs) appraised by eight HTA agencies and analyses synchronisation between the regulatory [...]

2022-10-26T17:22:25+00:00October 26th, 2022|Tags: , |
Go to Top